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Current Ebola virus outbreak in West Africa already reached the total number of
1,323 including 729 deaths by July 31st. the fatality is around 55% in the south-
eastern area of Guinea, Sierra Leone, Liberia, and Nigeria. The number of patients
with Ebola Hemorrhagic Fever (EHF) was continuously increasing even though the
any effective therapeutics or vaccines has not been developed yet. The Ebola
virus in Guinea showed 98% homology with Zaire Ebola Virus.
Study of the pathogenesis of Ebola virus infection and assess of the various
candidates of vaccine have been tried for a long time, especially in United States
and some European countries. Even though the attenuated live vaccine and DNA
vaccine containing Ebola viral genes were tested and showed efficacy in chim-
panzees, those candidates still need clinical tests requiring much longer time
than the preclinical development to be approved for the practical treatment.
It can be expected to eradicate Ebola virus by a safe and efficient vaccine
development similar to the case of smallpox virus which was extinguished from
the world by the variola vaccine.1. Introduction
In February 2014, the first outbreak case of Ebola
virus (Figures 1) was confirmed and registered in theted under the terms of the
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ase Control and Preventionregion of Guinea (West-Africa) by the World Health
Organization (WHO). By July 31, the total number of
suspected and confirmed cases in the Ebola hemorrhagic
fever (EHF) outbreak had increased to 1,323, includingCreative Commons Attribution Non-Commercial License (http://
ed non-commercial use, distribution, and reproduction in any
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Figure 1. Ebola virus virion under light microscopy. (Courtesy of CDC/Cynthia Goldsmith).
Ebola Hemorrhagic Fever 379729 deaths at a fatality rate of 55% in the southeastern
area of Guinea, Sierra Leone, Liberia, and Nigeria [1].
The Ebola virus in Guinea showed 98% homology with
the Zaire Ebola virus (ZEBOV) found in Congo and
Gabon (1994e1995) [2].
Since the first outbreak of Marburg hemorrhagic
fever occurred in 1967, there have been 18 reports of
human outbreaks by Ebola or Marburg viruses, which
has resulted in approximately 1,500 cases to date [3]
(Figure 2). In 1976, the first outbreak reported in Zaire
(Democratic Republic of the Congo) resulted in 318
cases and 280 deaths. Since then, Ebola virus epidemics
have occurred in several countries in equatorial Africa
and the strains were named after the regions of outbreak
including Ebola-Zaire, Ebola-Sudan, Ebola-Tai Forest,
Ebola-Bundibugyo, and Ebola-Reston. ZEBOV is the
most lethal pathogen of the Ebola viruses which causesFigure 2. Mapping the world Ebola outbreaks. http://www.ze> 90% of fatalities due to hemorrhagic fever in humans
and primates [4]. In 1994e1995, outbreaks in Gabon
and Zaire (Democratic Republic of the Congo) also
resulted in 285 deaths of 367 infected cases [5]. An
epidemiological study revealed that most cases occurred
after direct contact with blood, secretions, or tissue of
infected patients. In 1976, 27% of death cases among
88% of death cases in Zaire were reported as being due
to patients having been injected with a contaminated
syringe [6]. Mortality was higher even though the
percutaneous exposure was of very low Ebola virus
inocula. In 1995 in Kikwit, numbers of Ebola viral
particles found in human skin and lumina of sweat
glands raised concern about the disease transmission by
touching an infected patient or corpse [7]. The overall
window period ranges from 2 to 21 days, and patients
usually do not show any symptoms within the 1st week.rohedge.com/2014-04-05/mapping-workls-ebola-outbreaks.
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period does not appear to be common [8]. Ebola virus is
virulent in nonhuman primates and humans and could
cause serious acute infection with fever and a bleeding
diathesis after very short window period [9]. Usually,
patients infected with the Ebola virus show acute
symptoms with high fever, bleeding, disseminated
intravascular coagulation, headache, high fever, myal-
gias, nausea, abdominal pain, nonbloody diarrhea, ar-
thralgias, and malaise [10]. However, the ecology and
the epidemiology of Ebola viruses are poorly
understood.
EHF is a pathogenic symptom caused by one of four
major distinct hemorrhagic fever viruses (HFVs): Fla-
viviridae, Arenaviridae, Bunyaviridae, and Filoviridae.
HFVs belong to a group which generates febrile ill-
nesses by the RNA viruses of this viral family [11].
Naturally, HFVs are transmitted by animal hosts or
arthropod vectors, and the strains of the viruses each
have characteristic features and diseases. Flaviviridae
includes mosquito-borne yellow fever virus and Dengue
virus. Arenaviridae is well known and includes Lassa
virus and several South American HFVs transmitted by
small rodent contact. Bunyaviridae includes Rift Valley
fever (RVF) virus, Crimean-Congo hemorrhagic fever
(CCHF) virus, and Hantaan virus. RVF virus is trans-
mitted by mosquitoes and CCHF virus is transmitted by
ticks and is highly pathogenic for aerosol transmission
of infective particles.
The most notable HFVs, Ebola and Marburg viruses,
are classified as family Filoviridae, but the host species
in nature is still unknown [12]. Ebola and Marburg vi-
ruses give rise to a multitude of other human pathogens
like measles virus and respiratory syncytial virus in
Paramyxoviridae in structure and features; they have
negative-sense RNA without a segment as a genome
(approximately 15,000w16,000 bases) and have rapid
proliferation; the genome of Ebola virus is nearly 19,000
bases in length (Figure 3). This virus replicates genomes
and expresses proteins by the types of host cells with an
infecting capacity. Ebola virus is cytotoxic to cells and
may lead to thrombocytopenia, a platelet dysfunction.
The most important aspect of Ebola virus pathogenesis
is how it affects the immune responses of human and
nonhuman primates, which support the growth of Ebola
viruses.Figure 3. Negative-sense RNA genome of Ebola virus. Each ge
function of those genes are attenuated for live vaccine developmen
sGP Z soluble glycoprotein; VP Z viral protein such as RNA-binCommon diagnostic methods include antigen detec-
tion by antigen-capture enzyme-linked immunosorbent
assay (ELISA), immunoglobulin M (IgM)/IgG antibody
detection by ELISA, Realtime PCR, and virus isolation.
RT-PCR is the most common and useful diagnosis
technique, but antibody-capture ELISA has a limited
value in early diagnosis, because antibodies to these
viruses usually do not appear until the onset of recovery,
at 1w2 weeks of illness [13]. Otherwise, virus isolation
is also limited because it requires biosafety level 4
laboratories.
EHF is one of the aggressive infectious pathogens
which has no vaccine and prophylaxis. Preparedness
including vaccines, rapid treatment, and acute diagnostic
methods will be helpful for decreasing and managing of
infection as other infectious diseases. Regarding pre-
paredness, development of a vaccine is the best
approach to deal with the threat of high risk infectious
diseases.2. Ebola virus vaccine development
Study of the pathogenesis of Ebola virus infection
and assessment of various candidates for a vaccine have
been tried for a long time [14,15]. In the early stages of
research, live attenuated vaccines were studied using
guinea pigs and nonhuman primates as primary animal
models, because of the similar progression of symptoms
and pathogenesis to humans. However, no efficient
vaccine candidates were discovered even in nonhuman
primates. Recently, gene-based vaccine approaches
revealed advanced results in animals by several groups;
the Vaccine Research Center group of the National
Institute of Health (NIH) which collaborates with
research teams at the United States Army Military
Research Institute for Infectious Diseases (USAMRIID),
and British research groups including the Research
Institute for Tropical Medicine at Cambridge Univer-
sity. The Cambridge University group deals with vari-
able animal models with Ebola vaccine study in Africa,
and the Whitehead Institute at Oxford University
showed progression of a pathogenic characterization
study of Ebola virus which gives important clues for
vaccine and drug development. Early animal studies of
live attenuated vaccine with guinea pigs were notne transcribes functional proteins for viral replication. Some
t. GP Z glycoprotein; LZ polymerase; NPZ nucleoprotein;
ding protein or minor nucleoprotein.
Figure 4. Structure of vesicular stomatitis virus (VSV)-
based Ebola virus DNA vaccine. Ebola virus glycoprotein is
contained in the VSV protein in the plasmid.
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Research Center of NIH and Research Institute for
Tropical Medicine at Cambridge University announced
positive results about the efficacy of DNA vaccine
against Ebola virus in mice and chimpanzees. These
researches suggest a positive expectation for the devel-
opment of an Ebola vaccine [16]. We will briefly look at
each current candidate for an Ebola vaccine.
2.1. Live attenuated vaccine
In the 1990s, guinea pigs were used as an animal model
in Ebola virus vaccine research, mostly using live atten-
uated strains. Generally, live attenuated vaccine and re-
combinant protein vaccine have successful effects on
various pathogens, because they can be mucosally
administered [17,18]. Preliminary immunization studies
in mice and guinea pigs (unpublished data) indicated the
usefulness of vesicular stomatitis virus (VSV) vectors for
vaccine delivery against ZEBOV [19]. Based on attenu-
ated recombinant VSV (rVSV) including expressed Ebola
glycoprotein, replication-competent was developed
against ZEBOV. In the first study, using a vector
expressing the ZEBOV glycoprotein showed that the
nonhuman primates can be protected with a single dose
immunization [20]. In other cases, the utility and potential
of the rabies virus vaccine (RABV) vector platform,which
showed development of live and killed vaccines against
ZEBOV/Marburg virus, was studied. Immunization with
live RABV vaccines expressing ZEBOV glycoprotein
induced humoral immunity conferred protection from le-
thal ZEBOV/Marburg virus in mice [21]. However, there
has been no advance over two decades in the study of
Ebola virus vaccine and any animals tested obtained
protection by either live attenuated strains or recombinant
proteins used as vaccine candidates, even though mouse
models for efficacy testing were developed with mouse-
adapted Ebola virus strains. There could still be diffi-
culty for practical use, because there would be barriers in
the permission process and manufacturing procedures
raised by potential risks considering the extremely high
fatality of Ebola virus compared to other viruses, even if a
live attenuated vaccine could be developed.
2.2. DNA vaccine
From the late 1990s to the early 2000s, development
of a DNA vaccine has been continuously attempted,
which boosts immunization by delivering DNA into host
cells as an Ebola virus vaccine candidate. Insertion of
nucleoprotein and envelope glycoprotein for the purpose
of genetic immunization with plasmid DNA (vector) as
a DNA vaccine candidate was developed in some animal
models using guinea pigs and mice and resulted in a
high protection capacity [22,23].
In particular, DNA vaccine candidate containing
glycoprotein maintained memory for the immune
response for a long time to protect animals from Ebola
virus infection [24]. While primary DNA vaccineshave been highly effective in mice and other rodents,
their efficacy in nonhuman primates or humans has
been less impressive [25]. Many research groups,
including the NIH Vaccine Research Center, tried to
develop priming protocols of boosting immunization
for the improvement of efficacy, and some of those
protocols included a combination of viral vectors to
enhance the immune responses in human and
nonhuman primates [26].
In cases of DNA immunization followed by boosting
with poxvirus vector carrying the genes for pathogen
protein instead of plasmid, DNA vaccine produced
highly enhanced cellular immunity, over 30-fold.
Boosting with replication-defective adenovirus vectors
demonstrated a strengthening of stability for both
cellular and humoral immunity, enough to protect hosts
from the challenge of Ebola virus at the lethal dose. This
approach provides the first experimental demonstration
of vaccine candidates protecting primates from the
Ebola virus infection. About the same time, USAMRIID
successfully induced immune responses in primates
using a DNA vaccine candidate of a virus-like particle
(VLP). A VLP-type DNA vaccine can contain key
components of Ebola virus antigens to highly induce the
immune response; this VLP should be safe due to the
lack of full replication machinery.
Recently, a trial using VSV (Figure 4), designed to
contain the both Ebola and Marburg virus genes,
revealed regularly induced immune responses to protect
hosts [16,18]. So far, adenovirus vector, VSV vector,
and other DNA vaccines are in clinical trials. Not only
extermination of humans, but a lethal threat from the
Ebola virus to all chimpanzees, gorillas, and other
nonhuman primates in Africa and worldwide is another
dangerous issue of the wildlife ecosystem. A Cambridge
University group lead by Peter Walsh reported perfect
protection capacity of experimental vaccine using the
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Because the human immune system seems to be similar
to the system of chimpanzees against Ebola virus, this
type of DNA vaccine could be developed as a novel
candidate for human vaccine in the future.
3. Conclusion
To date, no vaccines have received regulatory
approval. However, there is still an outbreak and
spreading of EHF in Africa. The best preparedness
strategy against a crisis generated by high-risk viruses
like Ebola or Marburg viruses are to save stockpiles of
vaccines after development. As a warning of an
outbreak of EHF which has a lethal fatality just after
infection, immediate vaccination will be the most
effective response for the habitants of dangerous regions
against outbreaks; development of an effective vaccine
is essential as an advantage in controlling the spread of
disease. Above the development of this kind of vaccine
against high-risk pathogens such as Ebola virus, safety is
much more important than the efficacy to prevent po-
tential accidents.
Eradication of the Ebola virus by a safe and efficient
vaccine development similar to the case of the smallpox
virus, which was extinguished from the world by the
Variola vaccine developed by Edward Jenner, can be
expected.Conflicts of interest
The authors declare no conflicts of interest.
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